Nasus Pharma Ltd. (NSRX)
NSRX trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.16
-4.82% on the day
Market cap
$37.0M
Nano cap
Revenue · 2025
$1.2B
No prior year to compare
Net income · 2025
-$5.9M
-0.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | NSRX on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Not reported by the screener |
| IPO year | 2025 |
| SEC CIK | 0002029039 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | L3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.2B |
| Net income | -$5.9M |
| Operating income | -$4.9M |
| Net margin | -0.5% |
| Operating margin | -0.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $1.2M |
| Total assets | $5.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-18 |
| Latest annual report | 20-F | 2026-03-25 |
| Latest quarterly / interim | 6-K | 2026-10-08 |
Source: SEC EDGAR submissions feed, 99 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LITS | Lite Strategy Inc. | $1.21 | -0.82% | $36.8M |
| VERU | Veru Inc. | $2.19 | -8.94% | $37.3M |
| IXHL | Incannex Healthcare Inc. | $2.91 | +0.34% | $36.5M |
| FLNA | Filana Therapeutics Inc. | $0.7434 | -3.39% | $35.9M |
| EDSA | Edesa Biotech Inc. Common Shares | $2.85 | -3.23% | $38.4M |
| SCYX | SCYNEXIS Inc. | $3.99 | -0.99% | $39.7M |
| CRVO | CervoMed Inc. | $2.27 | -9.56% | $34.3M |
| IBO | Impact BioMedical Inc. | $3.98 | -1.24% | $34.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier